Martin Varsavsky Highlights Anthropic's Purchase of Mithril Medicine, a One Employee Biotech That Ran 11 Outside Labs With Claude
Anthropic, la empresa que creó Claude, acaba de comprar una biotech que tenía un solo empleado. Se llama Mithril Medicine y la fundó hace 18 meses Cody Tranbarger, que empezó como analista en Goldman Sachs y estudió biotecnología y MBA en Harvard. Su objetivo es un anticuerpo para la distrofia muscular congénita LAMA2, una enfermedad rara que aparece en bebés y niños. No tenía laboratorio propio. Tenía ocho consultores a tiempo parcial, 11 laboratorios externos y a Claude coordinando contratos, logística y experimentos. En menos de año y medio pasó de una idea a resultados prometedores en ratones, y Anthropic espera que pueda llegar a ensayos en humanos a finales de 2028. ¿Por qué importa tanto? Porque hasta ahora desarrollar un fármaco exigía equipos enormes y muchísimo capital, y una enfermedad con pocos pacientes casi nunca justificaba ese gasto. Por eso hay miles de enfermedades raras huérfanas, sin nadie que investigue para ellas. Si una persona con IA puede llevar adelante un programa entero, eso cambia. Cuando fundé Viatel y Jazztel, para llegar a cualquier cosa necesitabas mucho dinero y mucha gente. Hoy trabajo cada día con agentes de IA, y en Certuma vemos cómo un equipo pequeño hace lo que antes pedía una empresa entera. Mérito de Cody por animarse a probarlo primero, y con niños enfermos como objetivo. La próxima gran biotech quizás tenga un solo empleado.
Context
If one person with AI can run a full drug program, rare diseases that never justified big teams could get treatments developed.
Anthropic disclosed on Oct 27 that it had acquired Mithril Medicine in July. Founder Cody Tranbarger, who posted on X for years as @Prof_Oak_, confirmed the deal himself and said he joined Anthropic to continue the programs and lead its broader internal drug development work. Martin Varsavsky, the entrepreneur behind Viatel and Jazztel, wrote about the deal in Spanish on Nov 1.
Deep dive
Martin Varsavsky (@martinvars) wrote in Spanish on Nov 1 that Anthropic, the company behind Claude, has bought a biotech that had a single employee. The deal itself is confirmed: Anthropic disclosed on Oct 27 that it acquired Mithril Medicine in July, and founder Cody Tranbarger announced it on X and LinkedIn.
According to Varsavsky, Tranbarger founded Mithril 18 months ago after starting as an analyst at Goldman Sachs and studying biotechnology and business at Harvard. Mithril is working on an antibody for LAMA2 congenital muscular dystrophy, a rare disease that appears in babies and children. Varsavsky writes that it had no lab of its own, only eight part time consultants, 11 outside labs and Claude coordinating contracts, logistics and experiments, and that it went from an idea to promising mouse results in under a year and a half. He says Anthropic hopes it could reach human trials by late 2028.
Tranbarger's own account matches the outline. He wrote that with a single full time employee, consultants, a network of contract research labs and a whole lot of Claude, Mithril took a first in class idea through proof of concept in animals in less than 18 months. He calls the model Pipeline in a Person and says Mithril's programs became the first in Anthropic's internal pipeline. R&D World reports a second program targets trials as early as 2029.
Varsavsky argues the bigger point is cost: rare diseases with few patients rarely justified big teams, and he suggests the next big biotech may have one employee. That is his view.
What to expect next
Watch for Anthropic to share more on its internal drug pipeline, including whether it starts more programs run by single operators and whether it offers the approach to outside biotech companies. The key scientific test is whether the LAMA2 antibody keeps working in larger studies and reaches human trials on the late 2028 timeline Anthropic has given. Regulators and investors will also look at how much of the work Claude did versus the consultants and contract labs.